Reports Q3 revenue $11.78B, consensus $11.4B. Commenting on the quarter, Vas Narasimhan MD, CEO of Novartis, said: “Novartis delivered a very strong quarter, with double-digit sales and core operating income growth leading to a further upgrade to 2023 guidance. We have successfully executed the spin-off of Sandoz, allowing us to fully focus on high-value innovative medicines. Our growth drivers, including Kesimpta, Entresto, Kisqali and Pluvicto, continue to perform well in the market. Our robust pipeline also continues to deliver, and we have achieved important innovation milestones for Pluvicto, iptacopan, remibrutinib and Lutathera. We are confident in our mid-term growth outlook and remain committed to creating value for our shareholders.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on NVS:
- Novartis price target lowered to CHF 85 from CHF 90 at Barclays
- Novartis reports Phase III PSMAfore trial with Pluvicto met primary endpoint
- NVS Earnings this Week: How Will it Perform?
- Novartis price target lowered to CHF 74 from CHF 80 at Berenberg
- Novartis says NATALEE analysis reinforces reduction in risk of recurrence